Synovir thalidomide: CELG announced its plan for a Phase II/III pivotal trial

Celgene Corp. (CELG), Warren, N.J.
Product: Synovir thalidomide
Indication: Aphthous ulcers

Read the full 114 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE